360b-shutterstock-com-allergan-
360b / Shutterstock.com
29 September 2015Americas

Allergan survives Combigan patent challenge

Pharmaceutical company Allergan has survived an attempt by hedge fund Ferrum Ferro Capital (FFC) to invalidate a patent covering its Combigan (brimonidine and timolol) drug after the Patent Trial and Appeal Board (PTAB) opted not to institute an inter partes review (IPR).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
17 August 2015   US hedge fund Ferrum Ferro Capital has asked a California court to reject Allergan’s complaint about malicious prosecution because it allegedly violates a state law designed to stop parties from intentionally burdening another party with a legal complaint.

More on this story

Americas
17 August 2015   US hedge fund Ferrum Ferro Capital has asked a California court to reject Allergan’s complaint about malicious prosecution because it allegedly violates a state law designed to stop parties from intentionally burdening another party with a legal complaint.

More on this story

Americas
17 August 2015   US hedge fund Ferrum Ferro Capital has asked a California court to reject Allergan’s complaint about malicious prosecution because it allegedly violates a state law designed to stop parties from intentionally burdening another party with a legal complaint.